Table 4.

Comparison of COVID-19 positive ST-segment elevation myocardial infarction (STEMI) versus COVID-19 negative STEMI: procedural characteristics and clinical endpoints

	COVID-19 positive (n=46)	COVID-19 negative (n=302)	P value	OR (95% CI)
Procedural characteristics
Lesions treated	1 (1–1)	1 (1–1)	0.44
Vessels treated	1 (1–1)	1 (1–1)	0.53
Stents	1 (1–2)	1 (1–2)	0.99
Total length of stent (mm)	38 (24–48)	28 (20–38)	0.012*
Widest balloon (mm)	3.5 (2.5–3.75)	3.5 (3–4)	0.14
Cardiogenic shock	6 (13%)	41 (13.6%)	0.92	0.95 (0.40 to 2.30)
Gp2b3a inhibitor use	26 (56.5%)	117 (38.7%)	0.022*	2.06 (1.12 to 3.87)
Thrombus aspiration use	14 (30.4%)	54 (17.9%)	0.046*	2.01 (0.99 to 4.05)
TIMI flow <3 at end of case	9 (19.6%)	24 (8%)	0.012*	2.82 (1.16 to 6.45)
Clinical endpoints
ICU admission	15 (32.6%)	28 (9.3%)	<0.001*	5.74 (2.24 to 9.89)
Length of stay (days)	4 (3–9)	3 (2–4)	<0.001*
In-hospital mortality	10 (21.7%)	28 (9.3%)	0.012*	2.72 (1.25 to 5.82)

Procedural characteristics and clinical endpoints of patients with STEMI and concurrent COVID-19 and those without COVID-19 admitted during the study periods in 2020.

ICU, intensive care unit; TIMI, thrombolysis in myocardial infarction.